Delta wave activity disruption during sleep may be a useful metric to identify those at an increased risk for cardiovascular disease and mortality, a new study suggested.
The experimental siRNA agent led to prolonged Lp(a) reduction of more than 90%, extended data from the phase 1 trial show, supporting the move to phases 2 and 3 trials.
Modest financial incentives and gamification encouraged people with cardiovascular risks to meaningfully increase daily step counts over 18 months, in the BE ACTIVE trial.